<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02356965</url>
  </required_header>
  <id_info>
    <org_study_id>KET005</org_study_id>
    <nct_id>NCT02356965</nct_id>
  </id_info>
  <brief_title>Study Testing Ketamine Sublingual Wafer After Wisdom Tooth Extraction</brief_title>
  <official_title>A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Dose Ranging Study to Assess the Analgesic Efficacy, Tolerability, Safety and Pharmacokinetic/Pharmacodynamic Properties of A Sublingual Wafer Formulation of Ketamine Following Third Molar Extraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iX Biopharma Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jean Brown Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lotus Clinical Research, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>iX Biopharma Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to test two different doses of ketamine sub-lingual (under the
      tongue) wafer against placebo to see how effective the medication is to treat moderate to
      severe pain after wisdom tooth extraction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, randomized, double-blind, parallel group, dose-ranging placebo-controlled
      evaluation of the analgesic efficacy, safety and pharmacokinetics of ketamine sublingual
      wafer in adult subjects who experience post-operative pain after undergoing third molar
      extraction.

      The study will enroll approximately 80 subjects at a single site. Subjects will be at least
      18 years to 38 years of age. Subjects will receive a single dose of 70 mg or 100 mg
      sublingual ketamine wafer or placebo.

      Efficacy assessment will include pain intensity, use of rescue medication, and Patient Global
      Assessment (PGA) of pain control. Safety assessments will include monitoring of AEs and SAEs,
      clinical laboratory tests, vital sign measurements, oral assessments, and ECGs.

      A maximum of eight 4ml blood samples will be taken from each participant up to 8 hours after
      study drug administration for plasma analysis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sum of Pain Intensity Difference</measure>
    <time_frame>3 hours</time_frame>
    <description>Demonstrate the dose-response relationship for analgesia of two dose levels of ketamine sublingual wafer compared with placebo, using the summed pain intensity difference from baseline over the first 3 hours (SPID3) in subjects with acute moderate to severe pain following third molar extraction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sum of Pain Intensity Difference</measure>
    <time_frame>6 hours</time_frame>
    <description>Summed Pain Intensity Difference at 6 hours (SPID 6).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability evaluated by physical examination, vital signs, pulse oximetry, clinical laboratory tests, ECGs and Incident of Adverse Events (AEs) and Serious Adverse Events (SAEs).</measure>
    <time_frame>8 hours</time_frame>
    <description>Safety and tolerability of ketamine sublingual wafer as evaluated by physical examination, vital signs, pulse oximetry, clinical laboratory tests, ECGs and Incident of Adverse Events (AEs) and Serious Adverse Events (SAEs).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Ketamine 70 mg Sublingual Wafer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 70 mg ketamine sublingual wafer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine 100 mg Sublingual Wafer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 100 mg ketamine sublingual wafer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of placebo sublingual wafer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Single dose of sublingual investigational medication administered when subjects develop moderate to severe pain after third molar extraction.</description>
    <arm_group_label>Ketamine 70 mg Sublingual Wafer</arm_group_label>
    <arm_group_label>Ketamine 100 mg Sublingual Wafer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for Ketamine)</intervention_name>
    <description>Sublingual sugar pill developed to mimic ketamine sublingual dose.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Healthy male and female subjects, ages 18-38 years old, who are scheduled to undergo two
        ipsilateral third molar extractions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Derek D Muse, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jean Brown Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jean Brown Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2015</study_first_submitted>
  <study_first_submitted_qc>February 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2015</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Third molar extraction</keyword>
  <keyword>Wisdom tooth extraction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

